Intercept Pharmaceuticals Stock News

Investors are cheering the drugmaker's Q3 update.

Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics

Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.

Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.

Goldman Sachs cut Citigroup Inc. (NYSE: C) price target from $54 to $47. Citigroup shares fell 0.4% to $41.51 in pre-market trading. RBC Capital cut The Mosaic Company (NYSE: MOS) price target fro

Goldman Sachs raised Wells Fargo & Company (NYSE: WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40

Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 55.1% to $2.1411 after the company reported results from the additional preclinical study of its low-dose oral interferon formulation against Omicron.

U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Friday. Following the market opening Friday, the Dow traded down 0.22% to 29,160.17 while the NASDAQ rose 0.13

Poor earnings and a business setback were costly for these companies.

Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday. The post Intercept Pharmaceuticals Crashes After Drug Fails In Cir

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study Company remains on tra

Today is a big day for Intercept Pharmaceuticals (NASDAQ: ICPT ). The company just announced the clinical-trial results of Intercept's treatment for NASH cirrhosis.